Author

T. Mirtti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Approach:benchmark study· 1 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. Erickson· 3 shared A. Aakula· 1 shared A. D. Sahu· 1 shared A. Giesen· 1 shared A. Isomursu· 1 shared A. Kaur· 1 shared A. Kiviaho· 1 shared A. Padzik· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Erickson

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Immunosuppression in the prostate tumor microenvironment is tied to androgen deprivation therapy-resistant club-like cells

A. Kiviaho, S. K. Eerola, H. M. L. Kallio, M. K. Andersen, X. Spotbeen, A. Giesen, C. T. A. Parker, S. Taavitsainen, O. Hantula, M. Marttinen, I. Hermelo, M. Ismail, E. Midtbust, M. Wess, W. Devlies, , M. Nykter

The paper identifies club-like cells in the prostate tumor microenvironment that contribute to androgen deprivation therapy resistance through immune suppression.

bioRxiv · Mar 25, 2024 · PreprintCancer Biology

A Community Challenge to Predict Clinical Outcomes After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

M. Mason, O. Lapuente-Santana, A. S. Halkola, W. Wang, R. Mall, X. Xiao, J. Kaufman, J. Fu, J. Pfeil, J. Banerjee, V. Chung, H. Chang, S. D. Chasalow, H. Y. Lin, R. Chai, , B. G. Vincent

The paper evaluates predictive models for immune checkpoint inhibitor outcomes in NSCLC using clinical trial data from two RCTs, finding that models combining PD-L1, TMB, and immune signatures outperform single biomarkers.

Journal of Translational Medicine · Feb 21, 2024Peer-reviewedCancer Biology

IRF7 impacts on prostate cancer cell survival in response to radiation

A. Pickard, F. Amoroso, K. McCulloch, A. Erickson, A. Sachdeva, R. Steele, D. Mukherjee, M. Dellett, J. McComb, L. McCaffrey, C. Hart, M. Brown, S. S. McDade, D. Waugh, N. Clarke, , I. Mills

This study investigates how IRF7 influences prostate cancer cell survival after radiation and identifies therapeutic vulnerabilities linked to IRF7 expression.

bioRxiv · Sep 23, 2022 · PreprintCancer Biology

PME-1 suppresses anoikis, and is associated with therapy relapse of PTEN-deficient prostate cancers

A. Aakula, A. Isomursu, C. Rupp, A. Erickson, O. Kauko, P. Shah, A. Padzik, Y. R. Pokharel, A. Kaur, S.-P. Li, L. Trottman, P. Taimen, A. Rannikko, J. Lammerding, I. Paatero, , J. Westermarck

This study identifies PME-1 as a biomarker for aggressive PTEN-deficient prostate cancers by showing its role in suppressing anoikis.

bioRxiv · Mar 17, 2022 · PreprintCancer Biology